Alarmed that colleagues were bribing Chinese doctors and giving kickbacks to hospital workers to boost drug sales, an employee at the British pharmaceutical giant GlaxoSmithKline began documenting the alleged crimes in the fall of 2010 and sending detailed notes to the United States Securities and Exchange Commission and the U.S. Department of Justice. Using an anonymous email address, the GSK employee sent similar packages to regulators in China. No one responded — for years.  S